Hims & Hers Expands AI and Technology Focus to Advance Digital CareZacks Investment Research • 09/16/25
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's WhyZacks Investment Research • 09/15/25
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers PlatformGlobeNewsWire • 09/10/25
Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized TreatmentsBusiness Wire • 09/10/25
Trump aims to curb direct-to-consumer ads for drugs. Hims & Hers Health could be targeted.Market Watch • 09/09/25
Hims & Hers Expanding Partnerships to Build a Global Health EcosystemZacks Investment Research • 09/08/25
HIMS' Personalized Wellness Platform Expands Preventive Care AccessZacks Investment Research • 09/02/25
HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy?Zacks Investment Research • 08/28/25
HIMS & HERS ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 08/27/25
Hims & Hers Scales Growth Through Subscriptions and Care ExpansionZacks Investment Research • 08/27/25
Hims & Hers Health, Inc. Class Action: Levi & Korsinsky Reminds Hims & Hers Health, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – HIMSGlobeNewsWire • 08/25/25
HIMS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the August 25th Deadline for the Hims Lawsuit and Urges Investors to Contact The FirmGlobeNewsWire • 08/25/25